A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer

Completed · Phase 2

Conditions studied: Previously Treated Metastatic Pancreatic Cancer

In brief

The purpose of the study is selecting second line therapy for patients with pancreatic cancer using molecular profiling will improve 1 year survival.

Key facts

Study ID

NCT01196247

Run by

Translational Drug Development

People needed

35

Starts

2010-09-01

Expected to finish

2012-02-01

Last updated by the study team

2012-07-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• metastatic adenocarcinoma of the pancreas
• male or non-pregnant female
• 18 years of age or greater
• one prior therapy for the treatment of metastatic disease
• must start continuation therapy within 9 months of starting first line treatment
• have adequate organ and bone marrow function
• must have a Karnofsky performance status greater than or equal to 70
• one or more metastatic tumors measurable by CT scan and accessible for biopsy

You may not qualify if…

• operable or locally advanced pancreatic cancer
• metastatic tumor that is not amendable to biopsy
• known brain mets unless previously treated and well controlled
• active, uncontrolled bacterial, viral or fungal infections
• known infection with HIV, hepatitis B or hepatitis C
• pregnant or breast-feeding patients

Where it is running

• TGen Clinical Research Services at Scottsdale Healthcare — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.